Showing results (31-40 of 90) with videos related to
Sort By:
Pageof 9
Frontiers in Pharmacology|February 15, 2013
The discovery of dabigatran etexilateJoanne van Ryn, Ashley Goss, Norbert Hauel, et al.Thrombosis and Haemostasis|May 4, 2012
Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleedingRichard J Friedman, Andreas Kurth, Andreas Clemens, et al.International Orthopaedics|November 19, 2011
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]Ola E Dahl, Andreas A Kurth, Nadia Rosencher, et al.Thrombosis and Haemostasis|December 12, 2013
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY databaseGregory Y H Lip, Andreas Clemens, Herbert Noack, et al.Thrombosis Journal|April 5, 2016
Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical settingNadia Rosencher, Charles M Samama, Martin Feuring, et al.European Journal of Clinical Pharmacology|January 19, 2012
Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profileAndreas Clemens, Joanne van Ryn, Regina Sennewald, et al.Thrombosis Research|September 22, 2012
Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysisBengt I Eriksson, Ola E Dahl, Nadia Rosencher, et al.Thrombosis Research|December 9, 2008
Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR controlChristopher Ll Morgan, Phil McEwan, Andrzej Tukiendorf, et al.Current Medical Research and Opinion|January 3, 2012
Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justificationAndreas Clemens, Sebastian Haertter, Jeffrey Friedman, et al.Current Medical Research and Opinion|January 8, 2014
Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the USNils Schoof, Janet Schnee, Gary Schneider, et al.Pageof 9